Focus: Fosun Pharma is a publicly listed diagnostics and specialty pharma company headquartered in Sydney, Australia, with a diversified portfolio spanning oncology, neurology, cardiovascular, infectious disease, and respiratory therapeutic areas.
Profile data last refreshed 17h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Fosun Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Fosun Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Fosun Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship revenue driver representing 24% of company revenue with 11-year patent runway.
Significant post-LOE generic with moderate Medicare exposure; demonstrates generic competency but limited growth upside.
Branded version of abiraterone extending LOE to 2034; secondary franchise driver with moderate Medicare uptake.
Hedgehog pathway inhibitor in oncology/rare disease with 10-year patent protection; specialized but niche indication.
Mature bisphosphonate generic with stable but eroding Medicare reimbursement in competitive osteoporosis category.
183 discontinued, 106 duplicate formulations not shown
+3 more products with revenue data
Firms guide Fosun Pharma’s option agreement with AriBio - Law.asia
Firms guide Fosun Pharma’s option agreement with AriBio Law.asia
Fosun Pharma (02196)'s wholly owned subsidiary has received approval from the National Medical Products Administration for its drug registration application for levofloxacin injection. - Moomoo
Fosun Pharma (02196)'s wholly owned subsidiary has received approval from the National Medical Products Administration for its drug registration application for levofloxacin injection. Moomoo
Shanghai Fosun Pharmaceutical stock (CNE100000536): focus on pharmaceuticals and healthcare services - AD HOC NEWS
Shanghai Fosun Pharmaceutical stock (CNE100000536): focus on pharmaceuticals and healthcare services AD HOC NEWS
Fosun Pharma (02196)'s subsidiary has received approval from the National Medical Products Administration for its drug registration application for levofloxacin injection. - 富途牛牛
Fosun Pharma (02196)'s subsidiary has received approval from the National Medical Products Administration for its drug registration application for levofloxacin injection. 富途牛牛
Fosun Pharma (600196.SH): A drug developed by its controlling subsidiary has been approved to commence clinical trials in Australia. - 富途牛牛
Fosun Pharma (600196.SH): A drug developed by its controlling subsidiary has been approved to commence clinical trials in Australia. 富途牛牛
Shanghai Fosun Pharma Says Drug Registration Application For Levofloxacin Injection Approved By China's NMPA - TradingView
Shanghai Fosun Pharma Says Drug Registration Application For Levofloxacin Injection Approved By China's NMPA TradingView
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+77 more products
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo